Goldman Sachs Thinks Codiak BioSciences’ Stock is Going to Recover

Goldman Sachs analyst Andrea Tan maintained a Buy rating on Codiak BioSciences (CDAKResearch Report) today and set a price target of $8.00. The company’s shares closed last Tuesday at $2.98, close to its 52-week low of $2.50.

According to TipRanks.com, Tan is ranked 0 out of 5 stars with an average return of -34.5% and a 0.0% success rate. Tan covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Kodiak Sciences, and Vor Biopharma.

Currently, the analyst consensus on Codiak BioSciences is a Moderate Buy with an average price target of $8.00.

See Insiders’ Hot Stocks on TipRanks >>

Codiak BioSciences’ market cap is currently $64.78M and has a P/E ratio of -1.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

Read More on CDAK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed